3-Ethyl-2-methyl-4-oxo-3,4-dihydropyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并三嗪类
• 英文名称: 3-Ethyl-2-methyl-4-oxo-3,4-dihydropyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile
• 英文别名: 3-ethyl-2-methyl-4-oxopyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile
• 化学式: C₉H₉N₅O
• 分子量: 203.2
• InChiKey: PASADWWTGMQVLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  74.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (E)-N-4-cyano-1H-pyrazol-5-ylethanimidic acid ethyl ester 、 、 异氰酸乙酯 以 四氢呋喃 为溶剂， 反应 18.0h， 以to yield 3-ethyl-2-methyl-4-oxo-3,4-dihydropyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile (10 mg, yield 8.8%)的产率得到3-Ethyl-2-methyl-4-oxo-3,4-dihydropyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile
  参考文献：
  名称：

  PYRAZOLO COMPOUNDS AND USES THEREOF

  摘要：

  提供了一些化合物，可以用作一种或多种组蛋白去甲基化酶（如KDM5）的抑制剂。本发明还提供了包含本发明化合物的药学上可接受的组合物，并提供使用该组合物治疗各种疾病的方法。

  公开号：

  US20160060267A1

文献信息

• Pyrazolo compounds and uses thereof
  申请人：CONSTELLATION PHARMACEUTICALS, INC.

  公开号：US10035801B2

  公开（公告）日：2018-07-31

  Provided are compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the present composition in the treatment of various disorders.

  本发明提供了可作为一种或多种组蛋白去甲基化酶（如 KDM5）抑制剂的化合物。本发明还提供了包含本发明化合物的药学上可接受的组合物，以及使用本发明组合物治疗各种疾病的方法。
• US20140275092A1
  申请人：——

  公开号：——

  公开（公告）日：——
• METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES
  申请人：University of Houston System

  公开号：US20220202792A1

  公开（公告）日：2022-06-30

  The present disclosure provides methods and formulations for treating a patient suffering from one or more of chronic inflammatory injury, metaplasia, dysplasia or cancer of an epithelial tissue, which method comprises administering to the patient an agent that selectively kills or inhibits the proliferation or differentiation of pathogenic epithelial stem cells (PESCs) relative to normal epithelial stem cells in the tissue in which the PESCs are found. Representative epithelial tissues include pulmonary, genitourinary, gastrointestinal/esophageal, pancreatic and hepatic tissues.
• [EN] PYRAZOLO COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS PYRAZOLO ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2014139326A1

  公开（公告）日：2014-09-18

  Provided are compounds useful as inhibitors of one or more histone demethylses, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the present composition in the treatment of various disorders.
• [EN] METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES<br/>[FR] MÉTHODES ET COMPOSITIONS POUR TRAITER UNE LÉSION INFLAMMATOIRE CHRONIQUE, UNE MÉTAPLASIE, UNE DYSPLASIE ET DES CANCERS DES TISSUS ÉPITHÉLIAUX
  申请人：UNIV HOUSTON SYSTEM

  公开号：WO2020219963A1

  公开（公告）日：2020-10-29

  The present disclosure provides methods and formulations for treating a patient suffering from one or more of chronic inflammatory injury, metaplasia, dysplasia or cancer of an epithelial tissue, which method comprises administering to the patient an agent that selectively kills or inhibits the proliferation or differentiation of pathogenic epithelial stem cells (PESCs) relative to normal epithelial stem cells in the tissue in which the PESCs are found. Representative epithelial tissues include pulmonary, genitourinary, gastrointestinal/esophageal, pancreatic and hepatic tissues.